Connect your AI

XOMA Corporation XOMA Vabysmo — Rights Receivable Eir Method Receipt Of Payments

Similar metrics at other companies

VCYTBiopharmaceutical and other revenue — Accounts receivable

$1.1M-78.4%

UPSTPayments received on financing receivables

$1.37M—

PTGXAccrued revenue share

$53.66M—

TNETReceivable from sale of business

$0-100%

OSWReceivable Recorded In Connection With Divestitures Of Subsidiaries

$570.25K—

GLUEReceivable From Collaboration Agreement

$1.75M—

Other financials

Income statement

Revenue$12.3M-22.6%

Operating income-$480.0K-108%

Net income$4.5M+88.6%

EPS (diluted)$0.17+183%

Balance sheet

Cash & equivalents$85.6M-5.2%

Total debt$124.7M+9.0%

Total equity$92.9M+9.7%

Total assets$271.9M+27.8%

Cash flow

Operating cash flow$6.1M+178%

CapEx$3.0K-29.4%

Free cash flow-$2.9M+36.0%

Valuation

Market cap$746.04M+159%

Enterprise value$785.17M+152%

P/E22.1×—

P/S15.4×+8.7×

Profitability

Operating margin10.2%+5.5pp

Net margin69.6%+64.0pp

FCF margin-320%-118pp

Returns & leverage

Return on equity38.1%+35.2pp

Debt / equity1.3×0.0×

Current ratio3.6×-2.0×

Where this comes from

Reported directly by XOMA Corporation in its filing.

Tagged under the XBRL concept xoma:RightsReceivableEirMethodReceiptOfPayments.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's vabysmo — rights receivable eir method receipt of payments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is XOMA Corporation's vabysmo — rights receivable eir method receipt of payments?: XOMA Corporation (XOMA) reported vabysmo — rights receivable eir method receipt of payments of $11.95M in Q1 2026.
What does vabysmo — rights receivable eir method receipt of payments mean?: This metric tracks the actual cash inflows received from royalty-based financial assets associated with a specific therapeutic product. It represents the realization of economic rights previously acquired by the company. Monitoring these receipts is essential for evaluating the cash-generating performance of the underlying royalty asset.